CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems

CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems 

Plymouth Meeting, PA - September 2, 2010: CRF Health, a leading provider of ePRO solutions for the Life Sciences industry, today announced that the Company has recently completed the ePRO vendor certification program for use of the EXAcerbations of Chronic Pulmonary Disease Tool (EXACT). The EXACT is a patient-reported outcome (PRO) measure designed to standardize the method for evaluating the frequency, severity, and duration of acute exacerbations of chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) in U.S., as well as international based studies and clinical trials. Developed by United BioSource Corporation (UBC) through a unique multi-sponsor consortium approach involving input from clinical and methodological advisors and involvement of the U.S. Food and Drug Administration (FDA), the EXACT is the industry's only standardized tool for measuring exacerbations of COPD.
CRF Health has achieved certification for two devices currently in use with many ongoing projects; the HTC® HD2 and the HTC® Touch 2, which both use the Windows® Mobile operating system. "This certification allows CRF Health to meet the needs of our client base with regard to using the EXACT measure in their respiratory clinical studies, while giving our sponsor-clients confidence that the data collected via CRF Health's ePRO solutions will be captured in a consistent and proven manner," stated John Jordan, Senior VP of eClinical Technology for CRF Health.
When collecting EXACT data, clients have the option of a smaller screen device (HTC® Touch 2) or a larger screen (HTC® HD2), depending on the design of the clinical study and the clients' preferences.
"We are pleased to certify CRF Health on the electronic delivery of the EXACT and to continue our work with them in the use of the EXACT and other PROs in all types of clinical studies," said Sonya Eremenco, ePRO Manager at United BioSource Corporation and EXACT Certification Program Manager.
"CRF Health has collected ePRO data from hundreds of respiratory patients from around the world. The EXACT vendor certification further strengthens CRF Health's global, respiratory leadership position in the ePRO sector," Jordan concluded.
 
About CRF Health
CRF Health is a global leader in ePRO (electronic patient reported outcomes) solutions for the life sciences industry. Through innovative technology, a thorough understanding of drug development, and mobile computing, CRF Health is driving the change to higher quality outcomes and more efficient paper-free clinical trials.
CRF Health's ePRO technology has been used in more than 60 countries, on six continents and 68 regional languages, including several regional Indian dialects. CRF Health consistently demonstrates the industry's highest patient compliance rates, while delivering unrivaled data accuracy and unmatched patient and site acceptance.
Since its founding in 2000, CRF Health continues to provide true global ePRO delivery and service. Headquartered in the US, CRF Health operates its R&D center of excellence in Helsinki, Finland and has offices around the world.
 
About United BioSource Corporation

United BioSource Corporation (UBC) is a global scientific and medical affairs organization that partners with life science companies to develop and commercialize biopharmaceuticals, medical devices, and other health care products. We help deliver authoritative, real-world evidence to characterize product effectiveness, address safety risk, and demonstrate value. UBC brings together recognized scientific and industry experts, research operations professionals, and new technologies to provide innovative solutions across the product lifecycle. The company is headquartered in Bethesda, Maryland, with offices in North and South America, Europe and Asia. For more information about UBC, visit www.unitedbiosource.com.
Media Contact
Heather Bilinski, Marketing Coordinator
CRF Health
4000 Chemical Road, Suite 400
Plymouth Meeting, PA 19462
Phone: +1 267.498.2349
Fax: +1 215.565.0001
[email protected]

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.